Form 4: Regeneron Director Joseph L. Goldstein Acquires Stock and Options

Director Joseph L. Goldstein reports acquisition of Regeneron stock and options via restricted stock units and non-qualified stock options.

Summary

• On January 2, 2025, Joseph L. Goldstein, a director of Regeneron Pharmaceuticals, acquired 166 shares of common stock through time-based vesting restricted stock units, each representing a contingent right to receive one share.
• Goldstein also acquired 1,958 non-qualified stock options with an exercise price of $719.37.
• These options become exercisable in portions, starting from the date of the Issuer's first annual meeting of shareholders following the grant date, with the remainder exercisable on the first anniversary of the grant date, and expire on January 2, 2035.
• Following these transactions, Goldstein directly owns 6,548 shares of Regeneron common stock and 1,958 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of shares and options by a director is generally viewed as a positive sign, but it's not a major event.

Positives

• The acquisition of stock and options by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the stock options implies a long-term commitment from the director.

Industry Context

Acquisitions of company stock by directors are common and often viewed positively by investors, as they align the interests of management with those of shareholders. This is a routine disclosure related to insider transactions.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.

Key Dates